[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Nontuberculous Mycobacterial Infections - Pipeline Insight, 2019

October 2019 | 60 pages | ID: N347CF105607EN
DelveInsight

US$ 1,000.00 US$ 1,250.00 -20 %
Offer valid until December 31, 2019!

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
This report can be delivered to the clients within 48 Hours

'Nontuberculous Mycobacterial Infections - Pipeline Insight, 2019' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Nontuberculous Mycobacterial Infections pipeline landscape is provided which includes the disease overview and Nontuberculous Mycobacterial Infections treatment guidelines. The assessment part of the report embraces, in depth Nontuberculous Mycobacterial Infections commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Nontuberculous Mycobacterial Infections collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Nontuberculous Mycobacterial Infections Understanding

Nontuberculous mycobacterial (NTM) infections are caused by a group of microorganisms known by several different names including MOTT (mycobacteria other than tuberculosis), atypical mycobacteria, and environmental mycobacteria (unlike TB which is spread from person to person, these organisms are usually acquired from water or soil). These infections are often difficult to diagnose because the organisms must be cultured in the laboratory on special media. They are also challenging to treat because they require multiple antibiotics for extended periods, usually months to years. In some cases surgery may be required to control or cure the infection. The NTM most frequently causes lung infections but can involve soft tissues, bones or lymph nodes.

Nontuberculous Mycobacterial Infections Pipeline Development Activities

The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Nontuberculous Mycobacterial Infections targeted therapeutics development with respective active and inactive (dormant or discontinued) projects with the appropriate reasons if available. Nontuberculous Mycobacterial Infections pipeline report covers 6+ companies. Some of the key players include Savara Inc (Molgradex) Vertex Pharmaceuticals (SPR 720) etc.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university web sites and industry-specific third party sources, etc.

Nontuberculous Mycobacterial Infections Analytical Perspective by DelveInsight
  • In-depth Nontuberculous Mycobacterial Infections Commercial Assessment of products
This report provides an in-depth Commercial Assessment of therapeutic drugs have been included which comprises of collaborations, Licensing, Acquisition –Deal Value Trends. The sub-segmentation is described in the report which includes Company-Company Collaborations (Licensing / Partnering), Company-Academia Collaborations, and Acquisition analysis in both Graphical and tabulated form.
  • Nontuberculous Mycobacterial Infections Clinical Assessment of products
The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.

SCOPE OF THE REPORT
  • The Nontuberculous Mycobacterial Infections report provides an overview of therapeutic pipeline activity for Nontuberculous Mycobacterial Infections across the complete product development cycle including all clinical and non-clinical stages
  • It comprises of detailed profiles of Nontuberculous Mycobacterial Infections therapeutic products with key coverage of developmental activities including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details
  • Detailed Nontuberculous Mycobacterial Infections Research and Development progress and trial details, results wherever available, are also included in the pipeline study
  • Therapeutic assessment of the active pipeline products by development stage, product type, route of administration, molecule type, and MOA type
  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Nontuberculous Mycobacterial Infections
REASONS TO BUY
  • Establish a comprehensive understanding of the current pipeline scenario across Nontuberculous Mycobacterial Infections to formulate effective R&D strategies
  • Assess challenges and opportunities that influence Nontuberculous Mycobacterial Infections R&D
  • Develop strategic initiatives by understanding the focus areas of leading companies.
  • Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
  • Get in detail information of each product with updated information on each project along with key milestones
  • Devise Nontuberculous Mycobacterial Infections in licensing and out licensing strategies by identifying prospective partners with progressing projects for Nontuberculous Mycobacterial Infections to enhance and expand business potential and scope
  • Our extensive domain knowledge on therapy areas support the clients in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugs
1. REPORT INTRODUCTION

2. NONTUBERCULOUS MYCOBACTERIAL INFECTIONS

2.1. Nontuberculous Mycobacterial Infections Disease Overview
2.2. Nontuberculous Mycobacterial Infections History
2.3. Nontuberculous Mycobacterial Infections Symptoms
2.4. Nontuberculous Mycobacterial Infections Causes
2.5. Nontuberculous Mycobacterial Infections Pathophysiology
2.6. Nontuberculous Mycobacterial Infections Diagnosis
  2.6.1. Diagnostic Guidelines

3. NONTUBERCULOUS MYCOBACTERIAL INFECTIONS CURRENT TREATMENT PATTERNS

3.1. Treatment Guidelines

4. NONTUBERCULOUS MYCOBACTERIAL INFECTIONS- DELVEINSIGHT’S ANALYTICAL PERSPECTIVE

4.1. In-depth Commercial Assessment
  4.1.1. Nontuberculous Mycobacterial Infections companies collaborations, Licensing, Acquisition –Deal Value Trends
    4.1.1.1. Assessment Summary
  4.1.2. Nontuberculous Mycobacterial Infections Collaboration Deals
    4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
    4.1.2.2. Nontuberculous Mycobacterial Infections Acquisition Analysis
4.2. Clinical Assessment of Pipeline Drugs
  4.2.1. Assessment by Phase of Development
  4.2.2. Assessment by Product Type (Mono / Combination)
    4.2.2.1. Assessment by Stage and Product Type
  4.2.3. Assessment by Route of Administration
    4.2.3.1. Assessment by Stage and Route of Administration
  4.2.4. Assessment by Molecule Type
    4.2.4.1. Assessment by Stage and Molecule Type
  4.2.5. Assessment by MOA
    4.2.5.1. Assessment by Stage and MOA

5. NONTUBERCULOUS MYCOBACTERIAL INFECTIONS PIPELINE THERAPEUTICS

5.1. Late Stage Products (Phase-III)
  5.1.1. Comparative Analysis
5.2. Mid Stage Products (Phase-II)
  5.2.1. Comparative Analysis
5.3. Early Stage Products (Phase-I)
  5.3.1. Comparative Analysis
5.4. Pre-clinical and Discovery Stage Products
  5.4.1. Comparative Analysis
5.5. Inactive Products

6. NONTUBERCULOUS MYCOBACTERIAL INFECTIONS-PRODUCTS ANALYSIS

6.1. Product Profiles
  6.1.1. Molgradex- Savara Inc
    6.1.1.1. Product Description
      6.1.1.1.1. Product Overview
      6.1.1.1.2. Mechanism of Action
    6.1.1.2. Research and Development
      6.1.1.2.1. Clinical Studies
        6.1.1.2.1.1. Detailed Study Description
        6.1.1.2.1.2. Study Results
        6.1.1.2.1.3. Clinical Trials: Tabular View
    6.1.1.3. Product Development Activities
      6.1.1.3.1. Tabulated Product Summary
        6.1.1.3.1.1. General Description Table
  6.1.2. SPR 720- Vertex Pharmaceuticals
    6.1.2.1. Product Description
      6.1.2.1.1. Product Overview
      6.1.2.1.2. Mechanism of Action
    6.1.2.2. Research and Development
      6.1.2.2.1. Clinical Studies
        6.1.2.2.1.1. Detailed Study Description
        6.1.2.2.1.2. Study Results
        6.1.2.2.1.3. Clinical Trials: Tabular View
    6.1.2.3. Product Development Activities
      6.1.2.3.1. Tabulated Product Summary
        6.1.2.3.1.1. General Description Table

7. RECENT TECHNOLOGIES

8. NONTUBERCULOUS MYCOBACTERIAL INFECTIONS KEY COMPANIES

8.1. Savara Pharmaceuticals
8.2. Vertex Pharmaceuticals
8.3. Matinas BioPharma
8.4. Beyond Air
8.5. Hsiri Therapeutics
8.6. RedHill Biopharma

9. NONTUBERCULOUS MYCOBACTERIAL INFECTIONS KEY PRODUCTS

9.1. Molgramostim
9.2. SPR
9.3. Encochleated amikacin
9.4. Nitric oxide inhalation
9.5. Research programme: mycobacterial disease therapeutics
9.6. Clarithromycin/clofazimine/rifabutin

10. DORMANT AND DISCONTINUED PRODUCTS

10.1. Dormant Products
  10.1.1. Reasons for being dormant
10.2. Discontinued Products
  10.2.1. Reasons for the discontinuation

11. NONTUBERCULOUS MYCOBACTERIAL INFECTIONS- UNMET NEEDS

12. NONTUBERCULOUS MYCOBACTERIAL INFECTIONS- FUTURE PERSPECTIVES

13. APPENDIX

14. REPORT METHODOLOGY

14.1. Secondary Research
14.2. Expert Panel Validation

LIST OF TABLES

Table 1. Diagnostic Guidelines
Table 2. Treatment Guidelines
Table 3. Assessment Summary
Table 4. Company-Company Collaborations (Licensing / Partnering) Analysis
Table 5. Nontuberculous Mycobacterial Infections Acquisition Analysis
Table 6. Assessment by Phase of Development
Table 7. Assessment by Product Type (Mono / Combination)
Table 8. Assessment by Stage and Product Type
Table 9. Assessment by Route of Administration
Table 10. Assessment by Stage and Route of Administration
Table 11. Assessment by Molecule Type
Table 12. Assessment by Stage and Molecule Type
Table 13. Assessment by MOA
Table 14. Assessment by Stage and MOA
Table 15. Late Stage Products (Phase-III)
Table 16. Mid Stage Products (Phase-II)
Table 17. Early Stage Products (Phase-I)
Table 18. Pre-clinical and Discovery Stage Products
Table 19. Inactive Products
Table 20. Dormant Products
Table 21. Discontinued Products

LIST OF FIGURES

Figure 1. Disease Overview
Figure 2. History
Figure 3. Symptoms
Figure 4. Causes
Figure 5. Pathophysiology
Figure 6. Diagnostic Guidelines
Figure 7. Treatment Guidelines
Figure 8. Nontuberculous Mycobacterial Infections companies collaborations, Licensing, Acquisition –Deal Value Trends
Figure 9. Company-Company Collaborations (Licensing / Partnering) Analysis
Figure 10. Nontuberculous Mycobacterial Infections Acquisition Analysis
Figure 11. Assessment by Phase of Development
Figure 12. Assessment by Product Type (Mono / Combination)
Figure 13. Assessment by Stage and Product Type
Figure 14. Assessment by Route of Administration
Figure 15. Assessment by Stage and Route of Administration
Figure 16. Assessment by Molecule Type
Figure 17. Assessment by Stage and Molecule Type
Figure 18. Assessment by MOA
Figure 19. Assessment by Stage and MOA
Figure 20. Late Stage Products (Phase-III)
Figure 21. Mid Stage Products (Phase-II)
Figure 22. Early Stage Products (Phase-I)
Figure 23. Pre-clinical and Discovery Stage Products
Figure 24. Inactive Products
Figure 25. Dormant Products
Figure 26. Discontinued Products
Figure 27. Unmet Needs

KEY COMPANIES

Savara Pharmaceuticals
Vertex Pharmaceuticals
Insmed
Merck & Co
Matinas BioPharma
Beyond Air
Hsiri Therapeutics
Pfizer
RedHill Biopharma



More Publications